clinical trial · NCT07526792
SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
CSPC Megalith Biopharmaceutical Co.,Ltd.·phase3·not yet recruiting·n = 406
Urothelial CarcinomaSYS6002Investigator's Choice of Chemotherapy
brief summary
This study is a randomized, controlled, open-label, multicenter phase III clinical trial, which aims to evaluate the efficacy,safety PK characteristics, and immunogenicity of SYS6002 compared with chemotherapy in participants with locally advanced or metastatic urothelial carcinoma. This study has not yet been submitted for ethical review. The current registration is a pre-registration. Recruitment will commence only after formal approval is obtained from the relevant Ethics Committee).
started
Jun 20, 2026
primary completion
Jun 1, 2029
completion
Dec 1, 2029
last updated
Apr 13, 2026
official title
A Randomized, Controlled, Open-Label, Multicenter Phase 3 Trial of SYS6002 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure of Platinum-based Chemotherapy andPD-(L)1 Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol